Neonates With SARS-CoV-2 Infection and Pulmonary Disease Safely Treated With Remdesivir.
Pediatr Infect Dis J
; 40(5): e194-e196, 2021 05 01.
Article
in English
| MEDLINE | ID: covidwho-1180643
ABSTRACT
We describe 2 expremature infants presenting with SARS-CoV-2-related pulmonary disease in their second and fifth week of life needing support with mechanical ventilation. Both infants' initial presentation was with repeated apneas. These cases highlight that SARS-CoV-2 infection could present with apneas and has the potential to progress to more severe pulmonary disease in this high-risk age group of patients. Both patients were treated with remdesivir (RDV). We provide the data of 2 high-risk neonates successfully treated with RDV without observation of any described side effects. A recognition that these high-risk neonates could deteriorate and early multidisciplinary team discussion is the mainstay to the compassionate access to RDV. Our experience led us to develop a guideline on the use of RDV below 12 years of age, with particular focus on infants and young children.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Adenosine Monophosphate
/
Alanine
/
COVID-19 Drug Treatment
Type of study:
Case report
/
Diagnostic study
/
Observational study
/
Prognostic study
Limits:
Humans
/
Infant
/
Male
Country/Region as subject:
Europa
Language:
English
Journal:
Pediatr Infect Dis J
Journal subject:
Communicable Diseases
/
Pediatrics
Year:
2021
Document Type:
Article
Affiliation country:
INF.0000000000003081
Similar
MEDLINE
...
LILACS
LIS